The Medical Advisor

Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: October 13, 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of October 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side effects: what should patients know? Compounded, gray-market and research peptides: what are the risks? How strong is the evidence? (CEBM grades) Where to start: the complete GLP-1 evidence library Using...

Abstract Background: Drug repurposing has emerged as a strategy in oncology to identify low-cost, widely available agents with potential anticancer activity. Antiparasitic benzimidazoles (fenbendazole, mebendazole) and the macrocyclic lactone ivermectin have been proposed as adjunctive therapies in breast cancer based on preclinical mechanistic data and anecdotal clinical reports. Interest has grown within integrative oncology communities, particularly for advanced or treatment-resistant disease. Objective: To compile and summarize reported case experiences describing the use of fenbendazole, ivermectin, and mebendazole in patients with breast cancer, and to outline proposed biological mechanisms and current evidence gaps. Methods: Publicly available case reports, patient testimonials, and practitioner-shared clinical narratives involving breast cancer patients who used fenbendazole, ivermectin, or mebendazole were reviewed and categorized by disease stage, concurrent conventiona...